Rudy Ligtvoet

9PUBLICATIONS
33CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursProbability theoryPredictive and prognostic markersStatistical mechanics, physical combinatorics and mathematical aspects of condensed matter
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 14, 2026
Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.

Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht

|Feb 24, 2026
Impact of Perforin 1 A91V germ line background in patients with aggressive B-NHL treated with R-CHOP.

Onur Cetin, Igor Kos, Evi Regitz

|Dec 08, 2025
Impact of Perforin 1 A91V germ line background in patients with aggressive B-NHL treated with R-CHOP.

Onur Cetin, Igor Kos, Evi Regitz

|Sep 08, 2025
Efficacy of MRD-triggered anti-CD20 retreatment in patients with high-risk chronic lymphocytic leukemia: a case series.

Ellinor Goergen, Sandra Robrecht, Rudy Ligtvoet

|Sep 04, 2025
Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.

Florian Simon, Rudy Ligtvoet, Jan-Paul Bohn

|Jun 18, 2025
Inferences of associated latent variables by the observable test scores.

Rudy Ligtvoet

Pageof 2

Frequent Collaborators

5 joint publications

Michael J Hallek

4 joint publications

Sandra Robrecht

4 joint publications

Philipp Staber

3 joint publications

Othman Al-Sawaf